Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.160
-0.010 (-0.85%)
At close: Jul 3, 2025, 4:00 PM
1.130
-0.030 (-2.59%)
After-hours: Jul 3, 2025, 4:39 PM EDT
BCLI Employees
Brainstorm Cell Therapeutics had 27 employees as of December 31, 2024. The number of employees decreased by 2 or -6.90% compared to the previous year.
Employees
27
Change (1Y)
-2
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$410,593
Market Cap
9.21M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCLI News
- 17 days ago - BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PRNewsWire
- 5 weeks ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 6 weeks ago - Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - PRNewsWire
- 7 weeks ago - BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PRNewsWire
- 2 months ago - BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - PRNewsWire